Robert Reyes

A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.

D. Tribble, H. Bays, Neil J. Fraser, 2004, Clinical therapeutics.

Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

V. Elinoff, A. Elis, D. Maccubbin, 2008, International journal of clinical practice.

A multi‐centre, randomised, double‐blind 14‐week extension study examining the long‐term safety and efficacy profile of the ezetimibe/simvastatin combination tablet *

D. Tribble, T. Musliner, J. Lin, 2007, International journal of clinical practice.

Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.

D. Tribble, T. Musliner, L. Ose, 2007, Clinical therapeutics.

Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.

C. Ballantyne, J. Paolini, H. Bays, 2008, The American journal of cardiology.

Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire©: results from a randomised placebo-controlled clinical trial

J. Paolini, H. Bays, D. Watson, 2008, International journal of clinical practice.